Sylentis, a PharmaMar Group company, announces the results of the Phase III SYL1001_V trial with tivanisiran for the treatment of dry-eye disease associated with Sjögren’s Syndrome

The study that evaluated the efficacy of the drug did not meet the primary endpoint. Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with Sjögren’s Syndrome. The primary endpoint was to evaluate the efficacy (signs and symptoms) and was not met. The trial was a randomized, double-masked, placebo-controlled study conducted in more than 40 hospitals in the United States and 8 in Spain involving 203 patients. Sylentis would like to thank the patients, families, the hospitals, caregivers and the medical teams that have made it possible to carry out this trial.

The release as fetched from its publisher. pharmamar.com ↗